Abuse potential reduction in abusable substance dosage form
View Patent ↗The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.
1. A skin-worn transdermal patch device for the administration of an abusable substance to a patient, comprising:
(a) a deactivating layer in said patch device containing an amount of deactivating material that comprises one or more active deactivating substances for deactivating said abusable substance on contact, said one or more deactivating substances being selected from the group consisting of active binding agents including activated carbon for said abusable substance in said patch device, co-soluble antagonists, irritants and combinations thereof disposed in said deactivating layer;
(b) a source layer containing said abusable substance in said patch device;
(c) an impermeable separator membrane situated between said deactivating layer and said source layer preventing contact therebetween during normal use of said patch when said patch device is adhered to the skin of a user; and
(d) a membrane removal device connected to said separator membrane and provided with an aspect situated to adhesively attach to the skin of a user when said patch is applied; wherein said aspect and said patch are configured such that upon removal of said patch from skin to which said patch is adhered said aspect remains adhered to skin with sufficient adhesion to cause said separator membrane to be withdrawn from between said deactivating layer and said source layer upon removal of said patch so that the deactivating layer contacts the source layer.
2. A device as in claim 1 wherein said abusable substance is an opioid and said deactivating material is substantially activated carbon.
3. A device as in claim 1 wherein a portion of said activated carbon contains an amount of an agent selected from the group consisting of antagonists, irritants and mixtures thereof.
4. A device as in claim 1 wherein said deactivating material contains a binding agent that prevents separate extraction of said abusable substance of interest using a solvent selected from the group consisting of water, ethanol or combinations thereof.
5. A device as in claim 4 wherein said deactivating material includes activated carbon.
6. A device as in claim 4 wherein said deactivating material includes an amount of an agent selected from the group consisting of antagonists, irritants and combinations thereof.
7. A device as in claim 1 wherein said deactivating material includes activated carbon.
8. A device as in claim 1 wherein said deactivating material comprises:
(a) carbon in an activated state in a quantity sufficient to bind said opioid in said patch, and
(b) carbon that contains an amount of an incorporated species selected from the group consisting of irritating agents, antagonist agents and combinations thereof; and
(c) wherein said species is released from the carbon of (b) upon an attempt to solvent extract said abusable substance from the carbon of (a).
9. A device as in claim 8 wherein said deactivating material includes an amount of an irritant.
10. A device as in claim 8 wherein said deactivating material includes an antagonist.
11. A device as in claim 1 , wherein the membrane removal device comprises an integrally formed connector comprising an amount of adhesive which causes the connector to adhere to the skin of a user.
12. A device as in claim 1 , further comprising a patch adhesive overlayer which attaches the device to the skin.
13. A device as in claim 12 , wherein the overlayer comprises a cavity within which the deactivating layer, source layer, impermeable separator membrane and membrane removal device substantially fit when the device adheres to the skin of a user.